Innovation at Work
Colorado

Total Employment Supported by the Biopharmaceutical Sector
62,075

Total Direct and Indirect Economic Output of the Biopharmaceutical Sector
$14.5 billion

Local Perspective: Englewood, CO

"As a physician / rare cancer survivor, I am uniquely positioned to know firsthand the challenges faced by patients who are dealing with a rare disease diagnosis. Without research federal funding advancing the development of improved treatment options with potential for increasing survivorship is significantly diminished."

Erin Golden, 32, Postdoctoral Fellow at the University of Colorado Anschutz Medical Campus

Total NIH Award Funding (FY16)
$350 million

Local Perspective: Denver, CO

"Members of Congress should support scientific research because sustainable and predictable funding is essential for the development of new disease treatments and to maintain the health of our nation. The U.S. is a global leader in scientific and technological development and funding is vital to protecting this position."

Research in the Centennial State

Denver Health and Hospital Authority (DHHA), Denver, CO

The Agency for Healthcare Research and Quality (AHRQ) is funding DHHA research to advance appropriate emergency department use, which is expected to reduce avoidable healthcare costs and improve overall health care for the community.

The Immune Network and University of Colorado Denver School of Medicine, Aurora, CO

The University of Colorado School of Medicine and the Immune Network are conducting phase II clinical trials to test the safety and efficacy of two treatments for lupus nephritis, a potentially fatal autoimmune disease.

Gates Center for Regenerative Medicine, Aurora, CO

A completed seven-year NIH-funded study at the Gates Center has identified new pathways that head and neck cancer stem cells, which resist therapy and are a leading cause of relapsed cases of cancer, “hijack” to promote tumor growth. Increased understanding of how these stem cells promote tumor growth is a major step towards the development of new, more effective therapies.

SOURCES: NATIONAL INSTITUTES OF HEALTH, PHARMACEUTICAL RESEARCH AND MANUFACTURES OF AMERICAN (PHRMA), CENTERS FOR DISEASE CONTROL AND PREVENTION, A RESEARCHAMERICA SURVEY OF U.S. ADULTS CONDUCTED IN PARTNERSHIP WITH ZOGBY ANALYTICS IN JUNE 2016, AGENCY FOR HEALTHCARE RESEARCH AND QUALITY, CLINICALTRIALS.GOV, UC DENVER.